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What is Acute Kidney Injury (AKI)?
AKI is defined as any of the 
following:
•Increase in Serum Creatinine 
(SCr) by 0.3 mg/dl (X26.5 lmol/l) 
within 48 hours; or
•Increase in SCr to X1.5 times 
baseline, which is known or 
presumed to have occurred 
within the prior 7 days; or
•Urine volume ≤ 0.5 ml/kg/h for 
6 hours.
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Criteria
GFR criteria UO criteria
Stage 1
(Risk)
Increased creatinine x1.5 or
Increased by 0.3 mg/dL within 48 
hours
UO <0.5 ml/kg/h x 6 hours
Stage 2 
(Injury) 
Increased creatinine x2 (consider 
possible Renal Replacement 
Therapy)
UO <0.5 ml/kg/h x 12 hours
Stage 3
(Failure)
Increased creatinine x3 or SCr ≥4 
mg/dl 
UO <0.3 ml/kg/h x 24hours 
or anuria x 12 hours
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical 
practice guideline for acute kidney injury. Kidney Int 2:1–138
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Background
AKI occurs in more than 50% of all ICU patients.
Worsening AKI is associated with increased mortality.
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AKI and patient outcomes 
Bihorac, A., Yavas, S., Subbiah, S., Hobson, C., Schold, J., Gabrielli, A., ... & Segal, M. (2009). Long-term risk of mortality and acute kidney injury during 
hospitalization after major surgery. Annals of surgery, 249(5), 851.
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Contrast and AKI
McDonald, J. S., McDonald, R. J., Comin, J., Williamson, E. E., Katzberg, R. W., Murad, M. H., & Kallmes, D. F. (2013). Frequency of acute 
kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology, 267(1), 119-128.
Elevating care through discovery





























BHSF IT data warehouse
Match single stays At admission ± 24 hours 
& all subsequent times
KDIGO Creatinine Criteria AKI stage
< 1.5 × baseline and increase < 0.3 within 48 hrs 0
(1.5 to 1.9) × baseline or increase ≥ 0.3 within 48 hrs 1 Risk
(2.0 to 2.9) × baseline 2 Injury








<15 5 Very severe
Dialysis 6 End stage
Comparison 
groups
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Analysis sets
20,408 hospitalizations 2010-2014
with a single ICU stay ≥ 1 day
& no prior hospitalization < 30 days
LOS > 30 days
Discharged AMA or transfer
Discrepant ICU and hospital data
Missing APACHE or creatinine data
≥ 4 contrast
1st contrast ≥ 2 days post admit
14,461
AKI Stage 3 on admit
Future analysis
8,394
3,051 Contrast 5,343 No contrast 
Exclusions
CKD 3-5 on admit (N=6,033)
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Contrast, AKI and hospital death
Worsening AKI Stable AKI All
N % N % N %
Contrast 670 22.0 2,381 78.0 3,051 36.3
No contrast 1,075 20.1 4,268 79.9 5,343 63.7
All 1,745 20.8 6,649 79.2 8,394 —
Died Alive All
N % N % N %
Worsening AKI 291 16.7 4,381 83.3 1,745 20.8
Stable AKI 253 3.8 4,268 96.2 6,649 79.2
All 544 6.5 7,850 93.5 8,394 —
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Selective use of contrast
36.3% of study cases had contrast (3051 / 8394)
• 47.9% of patients hospitalized for cardiovascular 
disease (975 / 2037)
• 35.4% of diabetic patients (822 / 2321)
• 28.5% of patients with renal comorbidity (74 / 260)
• 8.0% of patients hospitalized for endocrine, 
metabolic or immune disorders (35 / 438)
Is contrast associated with AKI and hospital mortality 
after adjusting for factors that influence it’s use?
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Method—propensity score matching 
• Propensity score (PS)
• Predicted probability of receiving contrast ……
• ..… from regression model of contrast use (Y/N) in relation to many factors
• Used to match contrast cases to similar cases in the larger no-contrast pool
• Enables estimation of the relative risk of worsening AKI in matched sample
• PS model covariates
• Age, gender, race, BMI
• 12 categories of primary diagnosis; 7 categories on ICU admit 
• 13 comorbidities
• Severity scores: APS, APACHE, predicted ICU and hospital mortality
• Matching criteria 
• Propensity scores of matched pairs within 20% X σPS
• Same reference AKI stage
• Implemented in R MatchIt package (Ho et al. 2011)
Did we get a good match?
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2,749 (90%) of 3,051 contrast cases were matched





22.0 vs. 20.1% by contrast
6.5% died in hospital




21.5 vs. 19.3% by contrast
6.7% died in hospital
17.1 vs. 4.0% by worsening AKI
*RR of worsening AKI due to contrast
1.09 (95% CI: 1.0―1.2), p=0.047
RR of death due to worsening AKI
4.4 (95% CI: 3.7―5.1), p<0.001
RR of worsening AKI due to contrast
1.11 (95% CI: 1.0―1.2), p=0.048
RR of death due to worsening AKI
4.3 (95% CI: 3.5―5.2),  p<0.001
Unadjusted Propensity matched
*RR: Relative risk
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Does contrast affect the pattern of worsening AKI?
If not contrast, what?
• 1,122 (20.4%) patients developed worsening AKI
• 803 (71.6%) of these patients recovered
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Variable Odds Ratio 95% CI p-value 
Contrast 1.17 1.02 to 1.34 0.023 
Age, per 15 years 1.15 1.07 to 1.24 <.001 
Male vs female 1.21 1.05 to 1.39 0.007 
Black vs White, White Hispanic or Other  1.29 1.04 to 1.59 0.021 
BMI ≥ 30 (obese/morbidly obese) vs <30 1.14 0.98 to 1.33 0.096 
Primary diagnosis     
  Cardiovascular — reference — 
  Cerebrovascular or peripheral vascular  0.91 0.72 to 1.14 0.401 
  Digestive 1.34 1.05 to 1.30 0.019 
  Respiratory (parenchymal or airway) 1.56 1.25 to 1.94 <.001 
  Neoplasms 1.40 1.03 to 1.90 0.032 
  Injury/poisoning 1.21 0.90 to 1.64 0.214 
  Sepsis and other infections 2.35 1.78 to 3.11 <.001 
  Endocrine/metabolic/immune 2.08 1.17 to 3.70 0.012 
  Genitourinary 1.21 0.62 to 2.38 0.576 
  Other 1.45 1.06 to 1.97 0.020 
Comorbidity    
  HTN 1.13 0.97 to 1.32 0.129 
  Diabetes 1.37 1.18 to 1.60 <.001 
  CPD 1.23 1.05 to 1.44 0.004 
  CHF 1.62 1.37 to 1.93 <.001 
  Vascular 1.20 0.98 to 1.47 0.084 
  Cancer 1.08 0.85 to 1.35 0.536 
  Liver 1.80 1.42 to 2.28 <.001 
  Renal 5.83 4.02 to 8.47 <.001 
 
Factors associated with worsening AKI
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APACHE as a predictor of AKI
• 4,725 patients admitted to ICU within 1 day of hospital admit

























90th percentile APACHE (73)
Median APACHE (46)
10th percentile APACHE (27)
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Analysis recap
• The BHSF IT data warehouse is an excellent 
resource for retrospective research studies
• Time devoted to data cleaning and preparation 
always pays off and must be focused on a clear 
study objective and analysis plan
• In absence of randomization, propensity score 
methods can reduce confounding in retrospective 
studies to establish valid comparison groups
Elevating care through discovery
Clinical implications – So what?
•Contrary to current clinical belief, contrast 
should not be avoided when reasonably needed 
to treat critically ill patients
•Focus should be on prevention, reversal of 
renal ischemia, and maintenance of renal 
perfusion
•Prevent worsening AKI
•Implement KDIGO guidelines for early 
identification, early treatment and reversal of 
AKI
